Eyenovia

Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company based in New York, focused on developing innovative microdose therapeutics through its proprietary piezo-print delivery technology known as the Optejet. The company's aim is to enhance the delivery of ophthalmic pharmaceuticals by replacing traditional eye dropper methods, thereby improving safety, tolerability, and patient compliance for various eye treatments. Eyenovia's product pipeline includes several candidates: MicroLine, currently in Phase III development for presbyopia; MicroProst, also in Phase III trials for chronic angle closure glaucoma and ocular hypertension; MicroStat, which has completed Phase III trials for mydriasis; MicroTears for red eye and itch relief; and MicroPine for progressive myopia. The company seeks to address indications that lack FDA-approved drug therapies and was established in 2014, originally as PGP Holdings V, Inc., before rebranding to Eyenovia.